Limits...
Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.

Rovini A, Gauthier G, Bergès R, Kruczynski A, Braguer D, Honoré S - PLoS ONE (2013)

Bottom Line: Such effect was associated with a reduction of EB1 comet length at microtubule (+) ends.Interestingly, we found a correlation between the reduction of EB1 comet length by vinflunine and the inhibition of cell migration.Using 3-L-Nitrotyrosine incorporation experiments, we concluded that the EB1 C-terminal modifications result from a detyrosination/retyrosination cycle as described for tubulin.

View Article: PubMed Central - PubMed

Affiliation: Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale UMR_S 911, Marseille, France.

ABSTRACT
We previously showed that vinflunine, a microtubule-targeting drug of the Vinca-alkaloid family exerted its anti-angiogenic/anti-migratory activities through an increase in microtubule dynamics and an inhibition of microtubule targeting to adhesion sites. Such effect was associated with a reduction of EB1 comet length at microtubule (+) ends. In this work we first showed that the pro-angiogenic vascular endothelial growth factor VEGF suppressed microtubule dynamics in living Human Umbilical Vein Endothelial Cells (HUVECs), increased EB1 comet length by 40%, and induced EB1 to bind all along the microtubules, without modifying its expression level. Such microtubule (+) end stabilization occurred close to the plasma membrane in the vicinity of focal adhesion as shown by TIRF microscopy experiments. Vinflunine completely abolished the effect of VEGF on EB1 comets. Interestingly, we found a correlation between the reduction of EB1 comet length by vinflunine and the inhibition of cell migration. By using 2D gel electrophoresis we demonstrated for the first time that EB1 underwent several post-translational modifications in endothelial and tumor cells. Particularly, the C-terminal EEY sequence was poorly detectable in control and VEGF-treated HUVECs suggesting the existence of a non-tyrosinated form of EB1. By using specific antibodies that specifically recognized and discriminated the native tyrosinated form of EB1 and a putative C-terminal detyrosinated form, we showed that a detyrosinated form of EB1 exists in HUVECs and tumor cells. Interestingly, vinflunine decreased the level of the detyrosinated form and increased the native tyrosinated form of EB1. Using 3-L-Nitrotyrosine incorporation experiments, we concluded that the EB1 C-terminal modifications result from a detyrosination/retyrosination cycle as described for tubulin. Altogether, our results show that vinflunine inhibits endothelial cell migration through an alteration of EB1 comet length and EB1 detyrosination/retyrosination cycle.

Show MeSH

Related in: MedlinePlus

Anti-migratory vinflunine decreased EB1 comet length.(A) Number of migrating HUVECs in transwells following VFL treatment. *p≤0.001 (vs control, Student t test). (B) Concentration-dependent inhibition of cell survival by VFL after 72 h of treatment (C) Dose-response effect of VFL on EB1 comet length. * p≤0.05 (vs control, Student t test). (D) Correlation between EB1 comet length and the mean number of migrating cells/well.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3672205&req=5

pone-0065694-g004: Anti-migratory vinflunine decreased EB1 comet length.(A) Number of migrating HUVECs in transwells following VFL treatment. *p≤0.001 (vs control, Student t test). (B) Concentration-dependent inhibition of cell survival by VFL after 72 h of treatment (C) Dose-response effect of VFL on EB1 comet length. * p≤0.05 (vs control, Student t test). (D) Correlation between EB1 comet length and the mean number of migrating cells/well.

Mentions: We previously demonstrated that inhibition of U87 and HMEC-1 migration was correlated with EB1 comet length reduction [21], [22]. Here we explored VFL dose-response effect on endothelial cell migration and EB1 comet. In HUVECs, VFL suppressed migration in a concentration-dependent manner from 0.1 nM to 100 nM (Figure 4A, p<0.05) while concentrations required to inhibit cell viability were over 10 nM (Figure 4B). Moreover, VFL decreased EB1 comet length in a concentration-dependent manner, with a nearly complete disruption of EB1 at MT(+) ends at 100 nM (Figure 4C). Interestingly, we evidenced a strong correlation between the reduction of EB1 comet length and cell migration inhibition suggesting that such effect may contribute to the anti-migratory activity of VFL (Figure 4D). Altogether, our data suggest that the anti-migratory effect of VFL is correlated to EB1 comet disruption.


Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.

Rovini A, Gauthier G, Bergès R, Kruczynski A, Braguer D, Honoré S - PLoS ONE (2013)

Anti-migratory vinflunine decreased EB1 comet length.(A) Number of migrating HUVECs in transwells following VFL treatment. *p≤0.001 (vs control, Student t test). (B) Concentration-dependent inhibition of cell survival by VFL after 72 h of treatment (C) Dose-response effect of VFL on EB1 comet length. * p≤0.05 (vs control, Student t test). (D) Correlation between EB1 comet length and the mean number of migrating cells/well.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3672205&req=5

pone-0065694-g004: Anti-migratory vinflunine decreased EB1 comet length.(A) Number of migrating HUVECs in transwells following VFL treatment. *p≤0.001 (vs control, Student t test). (B) Concentration-dependent inhibition of cell survival by VFL after 72 h of treatment (C) Dose-response effect of VFL on EB1 comet length. * p≤0.05 (vs control, Student t test). (D) Correlation between EB1 comet length and the mean number of migrating cells/well.
Mentions: We previously demonstrated that inhibition of U87 and HMEC-1 migration was correlated with EB1 comet length reduction [21], [22]. Here we explored VFL dose-response effect on endothelial cell migration and EB1 comet. In HUVECs, VFL suppressed migration in a concentration-dependent manner from 0.1 nM to 100 nM (Figure 4A, p<0.05) while concentrations required to inhibit cell viability were over 10 nM (Figure 4B). Moreover, VFL decreased EB1 comet length in a concentration-dependent manner, with a nearly complete disruption of EB1 at MT(+) ends at 100 nM (Figure 4C). Interestingly, we evidenced a strong correlation between the reduction of EB1 comet length and cell migration inhibition suggesting that such effect may contribute to the anti-migratory activity of VFL (Figure 4D). Altogether, our data suggest that the anti-migratory effect of VFL is correlated to EB1 comet disruption.

Bottom Line: Such effect was associated with a reduction of EB1 comet length at microtubule (+) ends.Interestingly, we found a correlation between the reduction of EB1 comet length by vinflunine and the inhibition of cell migration.Using 3-L-Nitrotyrosine incorporation experiments, we concluded that the EB1 C-terminal modifications result from a detyrosination/retyrosination cycle as described for tubulin.

View Article: PubMed Central - PubMed

Affiliation: Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale UMR_S 911, Marseille, France.

ABSTRACT
We previously showed that vinflunine, a microtubule-targeting drug of the Vinca-alkaloid family exerted its anti-angiogenic/anti-migratory activities through an increase in microtubule dynamics and an inhibition of microtubule targeting to adhesion sites. Such effect was associated with a reduction of EB1 comet length at microtubule (+) ends. In this work we first showed that the pro-angiogenic vascular endothelial growth factor VEGF suppressed microtubule dynamics in living Human Umbilical Vein Endothelial Cells (HUVECs), increased EB1 comet length by 40%, and induced EB1 to bind all along the microtubules, without modifying its expression level. Such microtubule (+) end stabilization occurred close to the plasma membrane in the vicinity of focal adhesion as shown by TIRF microscopy experiments. Vinflunine completely abolished the effect of VEGF on EB1 comets. Interestingly, we found a correlation between the reduction of EB1 comet length by vinflunine and the inhibition of cell migration. By using 2D gel electrophoresis we demonstrated for the first time that EB1 underwent several post-translational modifications in endothelial and tumor cells. Particularly, the C-terminal EEY sequence was poorly detectable in control and VEGF-treated HUVECs suggesting the existence of a non-tyrosinated form of EB1. By using specific antibodies that specifically recognized and discriminated the native tyrosinated form of EB1 and a putative C-terminal detyrosinated form, we showed that a detyrosinated form of EB1 exists in HUVECs and tumor cells. Interestingly, vinflunine decreased the level of the detyrosinated form and increased the native tyrosinated form of EB1. Using 3-L-Nitrotyrosine incorporation experiments, we concluded that the EB1 C-terminal modifications result from a detyrosination/retyrosination cycle as described for tubulin. Altogether, our results show that vinflunine inhibits endothelial cell migration through an alteration of EB1 comet length and EB1 detyrosination/retyrosination cycle.

Show MeSH
Related in: MedlinePlus